Study guide

4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

Key Takeaways Explain This Topic AI

Treat contributors and organ complications while a specialist applies the current protocol or trial; complement-directed drug selection, dosing, vaccination/prophylaxis and monitoring are not universal.

Initial management stabilizes the patient, confirms the diagnosis, and removes or treats drivers such as infection, calcineurin inhibitor toxicity, and active GVHD before or alongside complement-directed therapy.

Terminal complement inhibition with a C5 inhibitor such as eculizumab or ravulizumab carries a boxed risk of life-threatening meningococcal infection, requiring meningococcal vaccination and/or antibacterial prophylaxis under the REMS program.

Capillary leak syndrome occurs early during conditioning or pre-engraftment with weight gain, edema, hypoalbuminemia, and intravascular depletion; unlike TA-TMA it is not defined by a microangiopathic hemolysis pattern, and albumin, diuresis, or corticosteroids are indication-specific rather than a universal bundle.

Engraftment syndrome is a noninfectious inflammatory syndrome temporally associated with neutrophil recovery, featuring otherwise unexplained fever, rash, pulmonary edema or hypoxemia, and weight gain; systemic corticosteroids may be used for clinically significant disease after infection, fluid overload, drug reaction, and GVHD are evaluated.

Last updated: September 2026

  • 1. Therapeutic Management and Complement-Directed Safety
  • Stabilize, Confirm, and Treat Drivers

Trend CBC, smear, LDH, haptoglobin, bilirubin, creatinine, urine protein, blood pressure, neurologic findings, and organ function; evaluate infection, GVHD, drugs, relapse, DIC, TTP, and other hemolysis.

Control severe hypertension and support renal, neurologic, respiratory, transfusion, and infectious needs. Avoid nephrotoxins when alternatives exist.

Review calcineurin/mTOR exposure and levels with the transplant team. A hold, dose change, switch, or continuation is individualized because abrupt withdrawal can worsen GVHD; “stop every CNI” is not a universal rule.

Plasma exchange is not standard TA-TMA monotherapy unless another indication such as TTP is suspected.

Complement-Directed Therapy

Eculizumab blocks cleavage of C5 and terminal membrane-attack-complex formation. Its use for TA-TMA is off-label ; selection, dosing, pharmacodynamic monitoring, response criteria, and duration follow specialist and center protocols. Other complement-directed approaches may be available through disease-specific programs or trials. Nurses verify the actual order and monitoring plan rather than applying a fixed transplant dose from memory.

Meningococcal Risk With C5 Inhibition

Current eculizumab labeling requires enrollment in the product REMS and meningococcal risk counseling. Give MenACWY and MenB vaccines according to current ACIP recommendations , ideally at least two weeks before the first dose when delaying therapy is safe. If urgent treatment begins before vaccination is complete or up to date, provide the antibacterial prophylaxis ordered under the label and clinical plan. Vaccination does not eliminate risk, and some experts consider prophylaxis for the treatment duration in selected patients, but the label does not mandate one universal antibiotic throughout therapy plus 60 days.

Teach the patient to carry the safety information and seek immediate evaluation for fever, severe headache, stiff neck, photophobia, confusion, myalgia with flu-like illness, or petechial/purpuric rash. Suspected meningococcal disease is an emergency even in a vaccinated patient.

2. Other Acute Post-Transplant Endothelial Syndromes

In addition to TA-TMA and SOS/VOD, nurses must recognize two additional acute post-transplant endothelial syndromes: Capillary Leak Syndrome and Engraftment Syndrome .

1. Capillary Leak Syndrome (CLS)

Timing & Mechanism: Occurs early during conditioning or pre-engraftment. Cytokines, infection, drugs, and conditioning injury can disrupt the endothelial barrier.

Clinical Manifestations: Weight gain, edema, hypoalbuminemia, hypotension or intravascular depletion, and organ dysfunction require urgent differential assessment.

Management: Treat the driver and support oxygenation/hemodynamics while balancing intravascular volume and edema. Albumin, diuresis, or corticosteroids are indication- and protocol-specific, not a universal bundle.

2. Engraftment Syndrome (ES) / Pre-Engraftment Syndrome

Engraftment syndrome is a noninfectious inflammatory syndrome temporally associated with neutrophil recovery, often featuring otherwise unexplained fever, rash, pulmonary edema/hypoxemia, weight gain, or organ dysfunction. Criteria differ, and infection, fluid overload, drug reaction, and GVHD must be evaluated. The team may use systemic corticosteroids for clinically significant disease while continuing supportive care and infection assessment.

Comparative Overview of Acute Post-HSCT Endothelial Syndromes

Feature TA-TMA SOS / VOD Capillary leak Engraftment syndrome

Dominant clue MAHA pattern, hypertension/proteinuria, organ injury Hepatic fluid-retention syndrome with bilirubin/weight/hepatomegaly criteria Generalized permeability and intravascular depletion Inflammation near neutrophil recovery

Key differential work TTP, DIC, relapse, infection, drugs GVHD, sepsis, drug/liver disease, heart failure Sepsis, anaphylaxis, cardiac/renal causes Infection, GVHD, drug reaction, overload

Management anchor Trigger/organ support; selected off-label complement therapy Supportive care; defibrotide when indicated Treat cause and balance hemodynamics Support; corticosteroid per severity/protocol

3. Diffuse Alveolar Hemorrhage and Idiopathic Pneumonia Syndrome

TA-TMA can involve the lung, but two additional non-infectious pulmonary syndromes belong in the same differential and are distinguished by how they are diagnosed rather than by how they look at the bedside. Both present as hypoxia with diffuse infiltrates in a patient who is often near neutrophil recovery, and both are diagnoses of exclusion that require an infectious workup first.

Diffuse alveolar hemorrhage (DAH) is bleeding into the alveolar space from injured pulmonary microvasculature. It presents with progressive dyspnea, hypoxia, and diffuse infiltrates, and notably hemoptysis is frequently absent , which is why it is missed. The diagnosis is made at bronchoscopy: serial bronchoalveolar lavage aliquots become progressively bloodier rather than clearing, and hemosiderin-laden macrophages support the finding. A falling hemoglobin without an external bleeding source in a hypoxic patient should prompt the question directly. Management is supportive with oxygenation and ventilatory support, correction of coagulopathy and thrombocytopenia, and specialist decisions about systemic corticosteroids.

Idiopathic pneumonia syndrome (IPS) is widespread alveolar injury with no identified infectious cause after a thorough evaluation including bronchoalveolar lavage. It presents with hypoxia, diffuse infiltrates, and restrictive physiology. Because the definition is exclusionary, the nursing contribution is ensuring the infectious workup is genuinely complete and that specimens were obtained before empiric therapy narrowed the picture.

Feature TA-TMA lung involvement Diffuse alveolar hemorrhage Idiopathic pneumonia syndrome

Supporting evidence Systemic MAHA pattern, hypertension, proteinuria Progressively bloodier serial BAL aliquots Diffuse injury with a negative infectious evaluation

Hemoptysis Uncommon Often absent despite alveolar bleeding Absent

Anchor of management Treat drivers; selected off-label complement therapy Support oxygenation; correct coagulopathy and platelets Support; specialist-directed anti-inflammatory decisions

4. What the Nurse Contributes to These Diagnoses

Every syndrome in this section is diagnosed from a trajectory rather than a single value, which makes serial nursing documentation the raw material for the diagnosis. Daily weights taken on the same scale at the same time, accurate intake and output, abdominal girth where ordered, oxygen requirement expressed as the delivery device rather than a saturation number alone, and blood pressure trends recorded against the patient's own baseline are the data the team uses to separate these overlapping syndromes.

Escalate the rate of change , not just the absolute value. A creatinine that has doubled inside forty-eight hours, an oxygen requirement that has climbed from room air to six liters over one shift, or a two-kilogram overnight weight gain each carry more diagnostic weight than any of those numbers do in isolation.